Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Fan Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3550-0243; OpenAlex author ID A5100373603. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 8

  1. Ultrasound-targeted microbubble destruction improves the suppression and magnetic resonance imaging of pancreatic cancer with polyethyleneimine nanogels. Last author DOI 10.7150/jca.93802↗
  2. Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer. Co-author DOI 10.1155/2022/4070060↗
  3. Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition … Last author DOI 10.1038/s41388-021-01762-0↗
  4. ERas regulates cell proliferation and epithelial-mesenchymal transition by affecting Erk/Akt signaling pathway in pancreatic cancer. Last author DOI 10.1007/s13577-020-00401-2↗
  5. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy. Co-author DOI 10.7150/thno.22834↗
  6. Role of microenvironmental periostin in pancreatic cancer progression. First author DOI 10.18632/oncotarget.11533↗
  7. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. First author DOI 10.1007/s13277-016-5321-6↗
  8. Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling. First author DOI 10.18632/oncotarget.9512↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peng Qin · 6 shared papers, 2016–2021 · strength 0.53
  2. Yang Liu · 2 shared papers, 2017–2024 · strength 0.38
  3. Feng Gao · 4 shared papers, 2016–2018 · strength 0.25
  4. Lizhou Lin · 4 shared papers, 2016–2018 · strength 0.25
  5. Junyan Wang · 1 shared paper, 2022 · strength 0.20
  6. Yanfeng Liu · 1 shared paper, 2022 · strength 0.20
  7. Lingxi Xing · 3 shared papers, 2016–2017 · strength 0.17
  8. Lianfang Du · 3 shared papers, 2016–2017 · strength 0.17
  9. Jiajie Zhang · 3 shared papers, 2016–2017 · strength 0.17
  10. Yang Liu · 1 shared paper, 2020 · strength 0.15
  11. Lianfang Du · 1 shared paper, 2020 · strength 0.15
  12. Yang Liu · 1 shared paper, 2021 · strength 0.13
  13. Lianfang Du · 1 shared paper, 2018 · strength 0.08
  14. Xiangyang Shi · 1 shared paper, 2018 · strength 0.08
  15. Dan Li · 1 shared paper, 2018 · strength 0.08
  16. Yang Liu · 1 shared paper, 2016 · strength 0.05
  17. Liu Yang · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.